Novel vaccine delivery devices market is projected to grow at an annualized rate of ~20% (till 2030)

Roots Analysis has done a detailed study on “Novel Vaccine Delivery Devices Market, 2019-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 500+ page report, which features 90+ figures and 160+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html

Key Market Insights

§  Over 130 novel vaccine delivery devices, including marketed / under development products, are being investigated for the delivery of both liquid and solid formulations for vaccines

§  The market landscape is fragmented, featuring both new entrants (small companies) and established players (mid-large sized enterprises); the US is currently considered to be the hub for vaccine delivery focused firms

§  A myriad of invasive and non-invasive delivery devices based on different routes of administrations are under evaluation; majority of them are in clinical stages of development

§  In order to achieve an edge over competing players, delivery device developers in this market are increasingly focusing on the integration of advanced features in their respective products / offerings

§  An evaluation of 490+ marketed and pipeline products revealed that several vaccine candidates are likely to be considered for delivery via novel vaccine delivery device in the near future

§  An increasing interest in the field is also reflected in the partnership activity, deals inked in the recent past were focused on a diverse range of devices, and involved both international and indigenous stakeholders

§  The benefits of the novel vaccine deliver devices presently outweigh the challenges related to their development and sales; the growing optimism in this domain is evident in the opinions of industry veterans

§  The future opportunity for novel vaccine delivery devices is expected to be distributed across various product types, routes of administration and key geographical regions

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html or email sales@rootsanalysis.com

Table of Contents

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.       An Overview of Vaccines
3.1.1.    Classification of Vaccines
3.1.1.1. Live, Attenuated Vaccines
3.1.1.2. Inactivated Vaccines
3.1.1.3. Subunit Vaccines
3.1.1.4. Toxoid Vaccines
3.1.1.5. DNA Vaccines

3.1.2.    Key Components of Vaccine Formulations
3.1.3.    Production of Vaccines in Different Expression Systems
3.1.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.1.3.2. Mammalian Expression Systems
3.1.3.3. Avian Expression Systems
3.1.3.4. Plant Expression Systems
3.1.3.5. Bacterial Expression Systems
3.1.3.6. Yeast Expression Systems
3.1.3.7. Insect Expression System

3.1.4.    Routes of Administration for Vaccines
3.1.4.1. Intradermal Route
3.1.4.2. Subcutaneous Route
3.1.4.3. Intramuscular Route
3.1.4.4. Oral Route
3.1.4.5. Intranasal Route
3.1.4.6. Inhalation

3.1.5.    Key Challenges Associated with Vaccine Delivery
3.1.6.    Novel Approaches for Vaccine Delivery Devices
3.1.6.1. Autoinjectors
3.1.6.2. Biodegradable Implants
3.1.6.3. Buccal / Sublingual Vaccine Delivery Systems
3.1.6.4. Electroporation
3.1.6.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.1.6.6. Jet Injectors
3.1.6.7. Microinjection System
3.1.6.8. Novel Oral Vaccine Formulations
3.1.7.    Future Perspectives

4.         MARKET LANDSCAPE
4.1.       Chapter Overview
4.2.       Marketed Vaccines Landscape
4.3.       Clinical-Stage Vaccines Landscape

4.4.       Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1.    Analysis by Type of Device
4.4.2.    Analysis by Route of Administration
4.4.3.    Analysis by Drug Delivery Mechanism
4.4.4.    Analysis by Nature of Vaccine Administration
4.4.5.    Analysis by Speed of Vaccine Administration
4.4.6.    Analysis by Self-Administration Potential
4.4.7.    Analysis by Availability of Audio / Visual Feedback
4.4.8.    Analysis by Device Usability
4.4.9.    Analysis by Type of Needle
4.4.10. Analysis by Stage of Development

4.5.       Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1.    Analysis by Type of Developer
4.5.2.    Analysis by Year of Establishment
4.5.3.    Analysis by Company Size
4.5.4.    Analysis by Geographical Location

5.         DEVICE COMPETITIVENESS ANALYSIS
5.1.       Chapter overview
5.2.       Assumptions and Methodology
5.2.1.    Device Competitiveness Analysis: Competitive Landscape

6.         TECHNOLOGY EFFECTIVENESS ANALYSIS
6.1.       Chapter Overview
6.2.       Assumptions and Key Parameters
6.3.       Methodology
6.4.       Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1.    Devices for Marketed Vaccines
6.4.1.1. Analysis by Type of Active Ingredient
6.4.1.2. Analysis by Dosage Form
6.4.1.3. Analysis by Route of Administration
6.4.1.4. Analysis by Target Disease Indication
6.4.1.5. Analysis by Target Patient Population
6.4.2.    Devices for Clinical-Stage Vaccines
6.4.2.1. Analysis by Type of Active Ingredient
6.4.2.2. Analysis by Dosage Form
6.4.2.3. Analysis by Route of Administration
6.4.2.4. Analysis by Target Disease Indication
6.4.2.5. Analysis by Target Patient Population

7.         NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1.       Chapter Overview
7.2.       Methodology and Key Parameters

7.3.       Marketed Vaccines
7.3.1.    Electroporation-based Needle Free Injection Systems: Likely Vaccine 
7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection SystemsSystems
7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems

7.3.2.    Jet Injectors: Likely Vaccine Candidates
7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.3.2.2. Likely Candidates for Delivery via Jet Injectors
7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.3.2.4. Least Likely Candidates for Delivery via Jet Injector

7.3.3.    Microneedle Patches: Likely Vaccine Candidates
7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.3.3.2. Less Likely Candidates for Delivery via Microneedle Patches
7.3.3.3. Least Likely Candidates for Delivery via Microneedle Patches

7.3.4.    Nasal delivery Systems: Likely Vaccine Candidates
7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems

7.3.5.    Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
 
7.3.6.    Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations

7.3.7.    Prefilled Syringes: Likely Vaccine Candidates
7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

7.4.       Clinical-Stage Vaccines
7.4.1.    Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.4.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.4.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems

7.4.2.    Jet Injectors: Likely Vaccine Candidates
7.4.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.4.2.2. Likely Candidates for Delivery via Jet Injectors
7.4.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.4.2.4. Least Likely Candidates for Delivery via Jet Injectors

7.4.3.    Microneedle Patches: Likely Vaccine Candidates
7.4.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.4.3.2. Likely Candidates for Delivery via Microneedle Patches
7.4.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.4.3.4. Least Likely Candidates for Delivery via Microneedle Patches

7.4.4.    Nasal Delivery Systems: Likely Vaccine Candidates
7.4.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.4.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems

7.4.5.    Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.4.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.4.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations

7.4.6.    Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.4.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.4.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations

7.4.7.    Prefilled Syringes: Likely Vaccine Candidates
7.4.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.4.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.4.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.4.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

8.         COMPANY PROFILES
8.1.       Company Overview
8.2.       3M
8.2.1.    Company Overview
8.2.2.    Financial Information
8.2.3.    Product Portfolio
8.2.3.1. 3M™ Hollow Microstructured Transdermal System
8.2.3.2. 3M™ Solid Microneedle
8.2.4.    Recent Collaborations
8.2.5.    Future Outlook

8.3.       Becton Dickinson
8.3.1.    Company Overview
8.3.2.    Financial Information
8.3.3.    Product Portfolio
8.3.3.1. BD Intevia™ Handheld Autoinjector
8.3.3.2. BD Accuspray™ Nasal Spray System
8.3.4.    Future Outlook

8.4.       Consort Medical
8.4.1.    Company overview
8.4.2.    Financial Information
8.4.3.    Technology Overview
8.4.4.    Product Portfolio
8.4.4.1. Autoinjectors
8.4.4.1.1. Syrina
8.4.4.1.2. OTS Autoinjector
8.4.4.2.   Nasal Delivery System
8.4.5.    Recent Collaborations
8.4.6.    Future Outlook

8.5.       D'Antonio Consultants International
8.5.1.    Company Overview
8.5.2.    Product Portfolio
8.5.2.1. LectraJet® High Speed Jet Injection System
8.5.2.2. LectraJet® M3 RA Needle-Free Injection System
8.5.2.3. LectraJet® M4 RA Needle-Free Injection System
8.5.2.4. Multi-Channel Jet Injector

8.6.       Enesi Pharma
8.6.1.    Company Overview
8.6.2.    Product Portfolio
8.6.2.1. Enesi ImplaVax®
8.6.3.    Recent Collaborations
8.6.4.    Future Outlook

8.7.       Ichor Medical Systems
8.7.1.    Company Overview
8.7.2.    Product Portfolio
8.7.2.1. TriGrid® Delivery System
8.7.3.    Recent Collaborations
8.7.4.    Future Outlook

8.8.       Iconovo
8.8.1.    Company Overview
8.8.2.    Financial Information
8.8.3.    Product Portfolio
8.8.3.1. ICOres
8.8.3.2. ICOone
8.8.3.3. ICocap
8.8.3.4. ICopre
8.8.4.    Recent Collaborations
8.8.5.    Future Outlook

8.9.       Inovio Pharmaceuticals
8.9.1.    Company Overview
8.9.2.    Financial Information
8.9.3.    Product Portfolio
8.9.3.1. ZetaJet®
8.9.3.2. Biojector® 2000
8.9.3.3. CELLECTRA® Electroporation Delivery Device
8.9.4.    Recent Collaborations
8.9.5.    Future Outlook

8.10.     PharmaJet
8.10.1. Company Profile
8.10.2. Product Portfolio
8.10.2.1. PharmaJet Stratis® Needle-Free Injector
8.10.2.2. PharmaJet Tropis® Intradermal Injection
8.10.3. Recent Collaborations
8.10.4. Future Outlook

8.11.     Union Medico
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.2.1. 45˚ Autoinjector
8.11.2.1.1. 45 ˚/ S Autoinjector
8.11.2.1.2. 45 ˚/ M Autoinjector
8.11.2.1.3. 45 ˚/ R Autoinjector

8.11.2.2. 90˚Autoinjector
8.11.2.2.1. 90 ˚ / S Autoinjector
8.11.2.2.2. 90 ˚ / M Autoinjector
8.11.2.2.3. 90 ˚ / XL Autoinjector
8.11.2.2.4. SuperGrip Autoinjector
8.11.2.2.5. Exclusive Autoinjector
8.11.3. Recent Development and Future Outlook

9.         PARTNERSHIPS AND COLLABORATIONS
9.1.       Chapter Overview
9.2.       Partnership Models
9.3.       Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1.    Analysis by Year of Partnership
9.3.2.    Analysis by Type of Partnership
9.3.3.    Analysis by Type of Device
9.3.4.    Analysis by Type of Partnership and Type of Device
9.3.5.    Analysis by Type of Vaccine and Type of Device
9.3.6.    Analysis by Type of Active Ingredient
9.3.7.    Analysis by Target Disease Indication
9.3.8.    Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9.    Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Intercontinental and Intracontinental Agreements

10.        SWOT ANALYSIS
10.1.     Chapter Overview
10.2.     Strengths
10.2.1. Minimally Invasive / Non-Invasive Vaccine Delivery
10.2.2. Ease of Use
10.2.3. Elimination of Cold-Chain Storage
10.2.4. Economic Advantages
10.2.5. Elimination of Medication Errors

10.3.     Weaknesses
10.3.1. Manufacturing Complexities
10.3.2. Cost Concerns
10.3.3. Product Stability Concerns

10.4.     Opportunities
10.4.1. Growing Pipeline of Vaccines
10.4.2. Increase in Self-Injecting Patient Population
10.4.3. Growing Incidence of Infectious Diseases
10.4.4. Innovation in Design and Technical Advancements
10.4.5. Geographic Expansions

10.5.     Threats
10.5.1. Competition from Conventional Delivery Systems
10.5.2. Strict Regulatory Framework

10.6. Concluding Remarks

11.        MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1.     Chapter Overview
11.2.     Forecast Methodology and Key Assumptions
11.3.     Global Novel Vaccine Delivery Device Market, 2019-2030
11.3.1. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Value)
11.3.1.1. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration 2019-2030 (By Value)
11.3.1.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine 2019-2030 (By Value)
11.3.1.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Value)
11.3.1.4.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030 (By Value)
11.3.1.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Value)
11.3.1.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Value)
11.3.1.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.1.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Value)
11.3.1.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Value)
11.3.1.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Value)
11.3.1.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Value)

11.3.2. Global Novel Vaccine Delivery Device Market, 2019-2030 (By Volume)
11.3.2.1. Global Novel Vaccine Delivery Device Market: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.2. Global Novel Vaccine Delivery Device Market: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.3. Global Novel Vaccine Delivery Device Market: Distribution by Type of Vaccine, 2019-2030 (By Volume)
11.3.2.4. Global Novel Vaccine Delivery Device Market: Distribution by Regions, 2019-2030 (By Volume)

11.3.2.4.1. Novel Vaccine Delivery Device Market in North America, 2019-2030 (By Volume)
11.3.2.4.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (By Volume)
11.3.2.4.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (By Volume)
11.3.2.4.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (By Volume)

11.3.2.4.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (By Volume)
11.3.2.4.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (By Volume)
11.3.2.4.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (By Volume)
11.3.2.4.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (By Volume)

12.        EXECUTIVE INSIGHTS
12.1.      Chapter Overview
12.2.      Vaxess Technologies
12.2.1.  Company Snapshot
12.2.1.1. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder

12.3.     Iconovo
12.3.1. Company Snapshot
12.3.1.1. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development

12.4.     Innoture
12.4.1. Company Snapshot
12.4.1.1. Interview Transcript: Henry King, Market Intelligence and Development Manager

13.        CONCLUDING REMARKS
13.1.     Chapter Overview
13.2.     Key Takeaways

14.        APPENDIX I: TABULATED DATA

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com